MiNK Therapeutics Inc | Needs refresh | Last updated: 2026-03-22T17:41:13Z
MiNK Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for CTLA-4 in developing potential first-or best-in-class therapies (Phase 2).
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| AGENT-797 | developing potential first-or best-in-class therapies | n/a | Phase 1 | Public pipeline row |
| CTLA-4 | n/a | n/a | Phase 2 | Public pipeline row |
| IL-15 | n/a | Cell Therapy | n/a | Public pipeline row |
| Nature Communications | n/a | Cell Therapy | Phase 1/2 | Public pipeline row |
| COVID-19 | n/a | Cell Therapy | n/a | Public pipeline row |
| Confirmatory Testing | n/a | n/a | n/a | Public pipeline row |
| AT-007 | Classic Galactosemia | n/a | Phase 2 | Phase 3 | Public pipeline row |
| RN6G | Age-Related Maculopathy | n/a | Phase 2 | Public pipeline row |
No public catalyst rows matched this view yet.
Estimated cash runway: Runway > 12 months.
This is an automated estimate and may differ from company guidance.
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| NCT01577381 | Phase 2 | TERMINATED | 10 | 2013-09 |
| NCT04902781 | Phase 2 | Phase 3 | COMPLETED | 47 | 2023-03-03 |
| NCT03655223 | n/a | ENROLLING_BY_INVITATION | 30000 | 2025-11-30 |
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.